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Abstract
Background and purpose—Hospital costs associated with atrial fibrillation (AFib) among 
stroke patients have not been well-studied, especially among people younger than 65 years. We 
estimated the AFib-associated hospital costs in U.S. patients aged 18-64 years.
Methods—We identified hospital admissions with a primary diagnosis of ischemic stroke from 
the 2010-2012 MarketScan Commercial Claims and Encounters inpatient datasets, excluding those 
with capitated health insurance plans, aged <18 or >64, missing geographic region, hospital costs 
below the 1st or above 99th percentile, and having carotid intervention (N=40,082). We searched 
the data for AFib and analyzed the costs for non-repeat and repeat stroke admissions separately. 
We estimated the AFib-associated costs using multivariate regression models controlling for age, 
sex, geographic region, and Charlson comorbidity index.
Results—Of the 33,500 non-repeat stroke admissions, 2,407 (7.2%) had AFib. Admissions with 
AFib cost $4,991 more than those without AFib ($23,770 vs. $18,779). For the 6,582 repeat stroke 
admissions, 397 (6.0%) had AFib. The costs were $3,260 more for those with AFib than those 
without ($24,119 vs. $20,929). After controlling for potential confounders, AFib-associated costs 
for non-repeat stroke admissions were $4,905, representing 20.6% of the total costs for the 
admissions. Both the hospital costs and the AFib-associated costs were associated with age, but 
not sex. AFib-associated costs for repeat stroke admissions were not significantly higher than for 
non-AFib patients, except for those aged 55-64 ($3,537).
Conclusions—AFib increased the hospital cost of ischemic stroke substantially. Further 
investigation on AFib-associated costs for repeat stroke admissions is needed.
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The prevalence of stroke, the fourth leading cause of death in the United States and a leading 
cause of long-term severe disability,1-2 is expected to increase dramatically in the coming 
years, owing to the aging population and increasing stroke survival rate.3 Stroke is one of 
the most expensive chronic diseases to treat, and the costs are projected to increase 
rapidly.3-7 For example, the estimated direct medical cost alone was $18.8 billion in 2008.4 
An even higher costs of $28.3 billion were projected for 2010 (in 2008 dollars), which 
would increase 238% between 2010 and 2030.6 Furthermore, the prevalence of stroke 
increases with age. Over two-thirds of stroke hospitalizations occur in those aged 65 and 
older, i.e., the nation’s Medicare recipients.8-10 Thus, stroke has been and will continue to be 
a significant public health problem in the United States. Because of the large aging 
population and the strong link between age and stroke, epidemiologic and economic 
research has focused on the population aged 65 and older. Yet, some studies have shown 
that the prevalence of stroke is increasing among younger adults.11-12 Investigation of the 
health and economic burden of stroke among those younger than 65 years is needed to guide 
public health interventions.
Atrial fibrillation (AFib) is a serious and common health condition, affecting between 2.5 
million and 6 million Americans, and is associated with a 4- to 5-fold increased risk of 
ischemic stroke.13-14 It is an independent risk factor for ischemic stroke severity, recurrent 
stroke, and mortality associated with stroke.13-17 Prevention of ischemic stroke in patients 
with AFib is potentially effective in reducing the disability and economic burden associated 
with stroke. In fact, many investigators have explored the cost-effectiveness of stroke 
prevention among patients with AFib.18-24 The role of AFib in the economic burden of 
stroke is still unknown, although many researchers have investigated the economic burden 
of both stroke and AFib separately.5-9, 25-31 Identifying AFib-associated economic burden 
among ischemic stroke patients could guide decision makers in resource allocations for 
developing public health programs. This information can also be valuable to researchers in 
the field, especially to those investigating cost-effective strategies for stroke prevention 
among patients with AFib. In this study, we estimated the AFib-associated hospital costs 
among ischemic stroke patients aged 18-64 years.
METHODS
Study population
Using the 2010-2012 MarketScan Commercial Claims and Encounters inpatient data set, we 
identified all hospitalizations with a primary diagnosis of ischemic stroke (International 
Classification of Diseases, Ninth Revision [ICD-9] codes 433, 434, 436). In each year, the 
data contained inpatient information on more than 1 million hospital admissions for 
privately insured patients, mainly for patients 64 years or younger, with comprehensive and 
high-quality coding of medical conditions and of hospital costs based on payments received 
by providers.32 It has been used by many researchers in estimating the economic burden of 
various health conditions, including cardiovascular disease. 28, 33-36 Because of the 
relatively low prevalence of stroke and AFib in adults younger than 65 years, we pooled 3 
years of MarketScan data to increase our sample size for this analysis. In selecting the study 
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sample (N=40,082, Figure 1), we excluded: 1) patients younger than 18 because of 
extremely low prevalence of stroke and AFib, and patients older than 64 because the 
extremely small number of these patients in this data set; 2) admissions with a capitated 
health insurance plan because their costs did not reflect the medical services they received; 
3) missing geographic region information because region is a major controlling variable in 
our study; 4) hospitalizations with a cost below the 1st or above 99th percentiles to reduce 
the influence of extreme values on the cost estimates; and 5) patients with an accompanying 
procedure code for carotid intervention (ICD-9 procedure codes 38,02, 38.12, 00.61, 00.63) 
because this study focused on the cost of acute stroke rather than an elective surgical 
procedure.
Among the stroke admissions, we searched the data for AFib including atrial flutter (ICD-9 
427.31 and 427.32).29 Our main outcome measure was the total hospital costs (total 
payments received by providers), including the costs for physician services, all diagnostic 
tests, therapeutics, supplies, and room fees during the stay. We evaluated the impact of AFib 
on the costs by length of stay (LOS). The average LOS was 5.2 days for patients with AFib 
and 3.9 days for patients without AFib. Therefore, we used 5 days as the cut point for our 
analysis. We controlled for age, sex, urbanization, geographic region, and Charlson 
Comorbidity Index (CCI). The CCI measured the likelihood of death or serious disability in 
the subsequent year by diagnosis codes for up to 18 different diseases to control the effects 
of disease severity and comorbidities on the costs.37-38
Statistical analysis
We conducted univariate comparison of the hospital costs between the hospitalizations with 
and without AFib by Wilcoxon two-sample test. Then, we specified various multivariate 
regression models to derive the AFib-associated costs. Because the data were at the hospital 
admission level rather than patient level, a patient included in the study might have multiple 
admissions during the study period. To estimate AFib-associated costs for initial stroke and 
recurrent stroke separately, we identified patients with non-repeat stroke admissions for 
ischemic stroke and analyzed the costs separately from those of repeat stroke admissions. 
An admission was classified as a non-repeat stroke admission if it was the only admission 
for a patient during the study period of 2010-2012; otherwise, it was classified as a repeat 
stroke admission. However, we were unable to confirm initial or recurrent stroke status due 
to the limitations of the data. We estimated the regression models using ordinary least 
squares for non-repeat stroke admissions, and mixed-effects with repeated-measure 
approaches for repeat stroke admissions.39-40 All statistical analyses were performed using 
SAS version 9.3 (Cary, NC: SAS Institute, Inc., Cary, NC).
RESULTS
We identified 40,082 hospital admissions with a primary diagnosis of ischemic stroke from 
2010-2012 in the MarketScan data files, of which 33,500 (2,407 [7.2%] with AFib, and 
31,093 without AFib) were non-repeat stroke admissions and 6,582 (397 [6.0%] with AFib, 
and 6,185 without AFib) were repeat stroke admissions (Figure 1). Compared to patients 
without AFib, a higher percentage of patients with AFib were older, male, residing in the 
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Northeast, and had a longer LOS (Table 1). For non-repeat stroke admissions, the mean 
costs were $19,138, and they were $4,991 (p<0.001) higher for patients with AFib than 
those without AFib (Table 2). This significant difference existed among all population 
groups by age, sex, urbanicity, geographic regions, and LOS. The largest differences were 
among patients aged 18-54 ($5,439) and those who resided in the West ($6,367). For repeat 
stroke admissions, the mean costs were $21,126. Although the costs were higher for 
admissions with AFib than those without, the differences were not statistically significant 
for repeat stroke admissions among most population groups.
After controlling for potential confounders, AFib increased the hospital costs by $4,905 
(p<0.001) for non-repeat stroke admissions, which is about 20.6% of the total hospital costs 
for patients with AFib (Table 3). AFib increased the costs of non-repeat stroke admissions 
by $5,084 (p<0.001) for patients aged 18-54 years and $4,854 (p<0.001) for patients aged 
55-64 years. The increased costs associated with AFib were similar by sex ($4,902 for men 
and $4,898 for women; both p<0.001). Admissions with LOS <5 days had $1,909 (p<0.001) 
higher costs for those with AFib compared to those without AFib. The cost increase 
associated with AFib was not statistically significant for admissions with a LOS ≥5 days. 
For repeat stroke admissions, AFib had a statistically significant effect on the hospital costs 
for patients aged 55-64 years only (mean cost increased by $3,537, p=0.005) (Table 3).
DISCUSSION
Our study may be the first comprehensive examination of the impact of AFib on hospital 
costs of ischemic stroke patients in a younger stroke population. After controlling for 
potential confounders, we found that AFib increased hospital costs for non-repeat ischemic 
stroke admissions by $4,905, accounting for 20.6% of the total hospital costs of admissions 
with AFib. Although not directly comparable, this cost difference for stroke admissions with 
AFib was lower than that derived by Kim et al. ($5,218),29 based on 2004-2006 MarketScan 
data. Using propensity score-matched subjects, Kim and colleagues compared inpatient 
costs between AFib and non-AFib patients aged 20 and older for all patients (i.e., without 
focusing on stroke patients). Their propensity score-matching technique improved their cost 
estimate, but deriving incremental costs by univariate comparison without further 
controlling for potential confounders might have led to an overestimate of the AFib-
associated costs. Using all patients (i.e., not limited to stroke or ischemic stroke patients) as 
their study subjects might also have overestimated the AFib-associated cost.
By focusing on ischemic stroke patients, we further found that both the costs of 
hospitalizations and the costs associated with AFib were higher in the younger age (18-54 
years) group compared to those aged 55-64 years. These findings are new and may have 
important public health implications. For example, while research and public health efforts 
have focused on stroke management and prevention among those aged 65 years or 
older,8, 9, 27, 31 stroke interventions such as AFib management among younger adults, as 
well as older adults, may have a greater economic impact. The higher costs associated with 
AFib suggests that stroke with AFib may be more severe than stroke without this 
disorder,13, 15-17 or it may reflect the added costs of diagnosis and treatment of previously 
undiagnosed AFib. Our findings may also suggest that younger patients aged 18-54 with 
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AFib-associated stroke were treated more aggressively than older patients aged 55-64 years 
old. 41, 42
Regardless of AFib status, overall hospital costs were similar for male and female patients. 
Moreover, the AFib-increased costs were also similar by sex ($4,902 for male and $4,898 
for female patients). This suggests that economically, AFib equally affected men and 
women. The hospital costs were higher for patients from urban areas compared to rural 
areas. It was clearly higher for patients from the West than from the other three regions of 
the United States. These geographic variations deserve further investigation. Another 
interesting finding was that for repeat admissions, the impact of AFib on the hospital costs 
was not statistically significant, except for patients aged 55-64. This may be due to the large 
cost variations among these admissions, as shown by the insignificant cost differences 
between AFib and non-AFib admission in Table 2. These issues deserve further exploration.
Our findings had several limitations. First, we selected the hospital admissions with a 
primary diagnosis of ischemic stroke for the cost analysis. This helped us to derive accurate 
estimates of the costs of ischemic stroke associated with AFib, but we might have missed 
stroke cases where acute stroke was listed as a secondary diagnosis. Indeed, there is a need 
to explore AFib-associated costs for those with a secondary diagnosis of stroke because a 
large proportion of stroke patients have stroke listed as a secondary diagnosis.28 Similarly, 
we did not include admissions with a primary diagnosis of AFib. This certainly led to a 
lower estimated cost associated with AFib.
Second, as with all studies that rely on medical records, the issue of coding error must also 
be considered. Although misdiagnosis issues have been investigated in the literature, how 
this issue would affect the costs in our study is unknown.43-45 Furthermore, AFib is often 
asymptomatic or clinically undetected; thus, AFib-associated stroke may be substantially 
underestimated.14 In addition, we may have missed AFib cases that were not identified 
during the hospital stays. A recent study found that 30-day ECG monitoring identified AFib 
in 5 times as many cryptogenic stroke patients compared to the standard 24-hour ECG 
monitoring post-stroke. A high proportion of cryptogenic stroke is later found to be 
associated with AFib.46
Third, although we distinguished repeat stroke admissions during the 3-year study period 
from non-repeat stroke admissions, we could not confirm initial stroke admission from 
recurrent stroke admission status. It is possible that some of the non-repeat stroke 
admissions were for a recurrent stroke. Because there was no way to confirm whether an 
admission was truly an initial or recurrent stroke admission, we were unable to further refine 
our analysis. Additionally, using CCI might not be sufficient to control for the impact of 
health conditions and stroke severely. Clinical information such as procedures and details 
cost categories are needed to shed more light on the AFib associated costs.
Finally, our study sample only contained patients aged 18-64 years with non-capitated 
private insurance plans, and thus the costs might be influenced by insurance reimbursement 
rate. The estimated hospital costs might be slightly higher than that of U.S. general 
population because it was an insured population.47 We expected that this did not severely 
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bias the estimation of AFib associated costs. While the prevalence of Afib in the younger 
population was much lower than in the 65 years and older population, we were not looking 
at total national burden of AFib and stroke. In addition to missing the stroke cases for 
patients without health insurance, with a capitated health insurance plan and government 
insurance coverage, we were unable to investigate the hospital costs among people older 
than 65 years. Because both stroke and AFib are strongly associated with age, investigating 
the relationship between stroke and AFib in the elderly population would be useful for 
policy makers in planning for a rapidly aging population. Despite these limitations, our cost 
estimates are valuable inputs for cost-effectiveness models such as comparing medical cost 
savings from high-quality anticoagulation services and patient home-testing of 
anticoagulation levels by AFib status or age groups.
CONCLUSIONS
We found that among non-repeat admissions for ischemic stroke, the hospital costs were 
substantial and varied by age and geographic area, and that AFib was an important 
contributor to the costs. Overall, AFib increased the hospital costs of ischemic stroke 
patients substantially across all age and sex groups. Particularly, both mean hospital costs 
and AFib-associated costs were higher for younger patients (aged 18-54 years) than older 
patients (aged 55-64 years) among non-repeat stroke admissions. Among repeat stroke 
admissions, AFib-associated costs were not statistically higher except for patients aged 
55-64 years. These findings can help to identify future research areas such as the need for 
separately examining the health and economic burden of initial and recurrent strokes, or 
evaluating cost-effectiveness of interventions for AFib and stroke prevention and control.
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Study population selection process, 2010-2012 MarketScan Commercial Claims and 
Encounters Database Inpatient Admissions
1An admission was a non-repeat stroke admission if it was the only admission for a patient 
during the study period of 2010-2012; otherwise, it was classified as a repeat stroke 
admission.
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Table 1
Characteristics of patients with a primary diagnosis of ischemic stroke, 2010-2012 MarketScan Commercial 
Claims and Encounters Database Inpatient Admissions
Total, %
1 Without AFib, % With AFib, % P-value
Non-repeat Stroke
Admissions
2 N=33,500 N=31,093 N=2,407
Age (years)
 18-54 41.5 42.7 25.6 <0.001
 55-64 58.5 57.3 74.4 <0.001
Average Age (years) 54.3 54.0 57.4 <0.001
Male 58.3 57.7 66.1 <0.001
Urban 82.1 81.9 83.8 0.018
Region
3
 Northeast 17.0 16.6 21.9 <0.001
 North Central 27.0 27.2 25.1 0.025
 South 44.0 44.4 38.1 <0.001
 West 12.1 11.8 15.0 <0.001
Charlson Comorbidity Index 3.2 3.2 3.3 0.014
(CCI) mean score
Length of Stay (LOS)
 <5 days 72.4 72.6 57.1 <0.001
 ≥5 days 27.6 26.4 42.9 <0.001
Average LOS (days) 4.1 4.0 5.2 <0.001
Repeat Stroke Admissions N=6,582 N=6,185 N=397
Age
 18-54 43.0 44.3 26.4 <0.001
 55-64 57.0 55.7 73.6 <0.001
Average Age (years) 54.1 53.8 57.5 <0.001
Male 57.0 56.7 62.2 0.003
Urban 82.2 82.2 81.9 0.847
Region
 Northeast 22.3 22.1 26.4 0.042
 North Central 27.0 27.0 28.0 0.667
 South 41.9 42.2 37.8 0.083
 West 8.7 8.7 7.8 0.520
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Total, %
1 Without AFib, % With AFib, % P-value
Non-repeat Stroke
Admissions
2 N=33,500 N=31,093 N=2,407
CCI mean score 3.4 3.4 3.6 0.070
LOS
 <5 days 57.9 58.4 50.4 0.002
 ≥5 days 42.1 41.6 49.6 0.002
Average LOS (days) 6.5 6.5 6.8 0.451
1
All values are percentages unless otherwise indicated.
2
An admission was a non-repeat stroke admission if it was the only admission for a patient during the study period of 2010-2012; otherwise, it was 
classified as a repeat stroke admission.
3
Northeast region includes Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, and 
Pennsylvania; North Central region includes Illinois, Indiana, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North 
Dakota, and South Dakota; South region includes are Washington D.C., Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, 
Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, and Texas; West region includes Arizona, 
Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming, Alaska, California, Hawaii, Oregon, and Washington.
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Table 2
Mean hospital costs (2012 $) of patients with a primary diagnosis of ischemic stroke, by atrial fibrillation 
(AFib) status, 2010-2012 MarketScan Commercial Claims and Encounters Database Inpatient Admissions







1 N=33,500 N=31,093 N=2,407
Total 19,138 18,779 23,770 4,991 (< 0.001)
Age (years)
 18-54 19,710 19,469 24,908 5,439 (<0.001)
 55-64 18,732 18,263 23,379 5,116 (<0.001)
Sex
 Male 19,194 18,786 23,802 5,016 (<0.001)
 Female 19,058 18,769 23,709 4,939 (<0.001)
Metropolitan Statistical Area
 Yes 19,489 19,128 24,047 4,920 (<0.001)
 No 17,531 17,199 22,332 5,133 (<0.001)
Region
2
 Northeast 19,757 19,341 23,841 4,500 (<0.001)
 North Central 18,773 18,473 22,969 4,496 (<0.001)
 South 17,962 17,685 22,133 4,448 (<0.001)
 West 23,365 22,796 29,163 6,367 (<0.001)
Length of Stay (LOS)
 <5 days 14,322 14,203 16,314 2,111 (<0.001)
 ≥5 days 31,798 31,558 33,704 2,147 (=0.014)
Repeat Stroke N=6,582 N=6,185 N=397
Admissions
Total 21,126 20,929 24,199 3,269 (=0.002)
Age (years)
 18-54 21,634 21,487 25,471 3,985 (=0.053)
 55-64 20,741 20,487 23,741 3,254 (=0.007)
Sex
 Male 21,228 20,850 26,582 5,732 (<0.001)
 Female 20,992 21,033 20,273 −759 (=0.643)
Metropolitan Statistical Area
 Yes 21,744 21,623 23,640 2,017 (=0.087)
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1 N=33,500 N=31,093 N=2,407
 No 18,270 17,716 26,719 9,003 (<0.001)
Region
 Northeast 22,525 22,398 24,164 1,765 (=0.391)
 North Central 20,785 20,546 24,383 3,837 (=0.041)
 South 19,584 19,388 23,002 3,615 (=0.028)
 West 26,037 25,842 29,444 3,602 (=0.439)
LOS
 <5 days 13,912 13,899 14,157 259 (=0.727)
 ≥5 days 31,042 30,786 34,393 3,607 (=0.058)
1
An admission was a non-repeat stroke admission if it was the only admission for a patient during the study period of 2010-2012; otherwise, it was 
classified as a repeat stroke admission.
2
Northeast region includes Connecticut, Maine, Massachusetts, New Hampshire, Rhode Island, Vermont, New Jersey, New York, and 
Pennsylvania; North Central region includes Illinois, Indiana, Michigan, Ohio, Wisconsin, Iowa, Kansas, Minnesota, Missouri, Nebraska, North 
Dakota, and South Dakota; South region includes are Washington D.C., Delaware, Florida, Georgia, Maryland, North Carolina, South Carolina, 
Virginia, West Virginia, Alabama, Kentucky, Mississippi, Tennessee, Arkansas, Louisiana, Oklahoma, and Texas; West region includes Arizona, 
Colorado, Idaho, Montana, Nevada, New Mexico, Utah, Wyoming, Alaska, California, Hawaii, Oregon, and Washington.
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Table 3
Atrial fibrillation associated hospital costs (2012 $) for patients with a primary diagnosis of ischemic stroke, 
2010-2012 MarketScan Commercial Claims and Encounters Database Inpatient Admissions
1






































Controlling variables are age, sex, metropolitan statistical area, region, Charlson Comorbidity Index score, and years.
2
An admission was a non-repeat stroke admission if it was the only admission for a patient during the study period of 2010-2012; otherwise, it was 
classified as a repeat stroke admission.
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